The Alzheimer Society Research Portal connects researchers with Canadians looking to participate in research studies. On this website, find active studies that you can participate in to help advance research on dementia.
Quick Searches
Selecting one or more of the options below will update the content below.
- Observational StudyOnline
What is this Study about?
This study explores dementia stigma within South Asian communities in Canada, a group that has been underrepresented in dementia research. Using a focused ethnographic approach, it aims to understand community beliefs and experiences related to dementia and identify ways to create a culturally appropriate dementia-friendly society.
The study will: Examine South Asian cultural understandings of dementia and dementia-related stigma. Investigate how dementia affects the overall well-being of people living with dementia, their families, and caregivers. Explore how individuals make decisions about seeking healthcare and support. The research also seeks to understand how social, cultural, structural, and political factors contribute to dementia stigma and how culturally relevant anti-stigma interventions can be developed.
Expected outcomes include: Generating new knowledge about dementia stigma in South Asian communities. Increasing awareness and promoting dementia-friendly environments. Sharing findings through academic publications, conferences, community presentations, and multilingual infographics in Bengali, Hindi, and Urdu to reach a broader audience.
Eligibility Criteria
You are eligible to participate if you:
- live with dementia or provide care for a loved one living with dementia
- live in the Greater Toronto and Hamilton Area (GTHA)
- connect your roots or ethnicity to Bangladesh, India, or Pakistan
- are sixteen years of age or older
- can provide consent
- speak English, Hindi, Urdu, or BengaliRecruitment End Date
- Observational StudyOnline
What is this Study about?
In the past, frailty and dementia were treated as distinct entities; however, it is now recognized that they share a complex relationship. As a result, there is an urgent need for the joint investigation of frailty and dementia. Our survey aims to bring together perspectives from stakeholders worldwide who share an interest in frailty and dementia. We are collecting data over the next several months, via various promotional "waves." Once we reach adequate participation and thematic saturation, we anticipate that data analysis and knowledge dissemination will take approximately six months.
Eligibility Criteria
- You are 18 years of age or older.
- You have an interest in frailty and dementia.
- This includes researchers, healthcare professionals, policy and decision-makers, older adults, care partners, advocates, and others with relevant interest or experience.
- You speak English.
Recruitment End Date
- Observational StudyOnline
What is this Study about?
This study evaluates an at-home, digital cognitive screening tool for older adults experiencing memory changes across the dementia continuum. Participants will complete a brief series of engaging, online brain games and surveys to determine the tool's accuracy compared to traditional clinical assessments. The goal of this study is to provide accessible, patient-friendly monitoring of brain health that reduces the need for clinic travel and lowers barriers to early detection of dementia.
Eligibility Criteria
You are eligible to participate if you:
Are 50 years of age or older
Either have healthy cognition or are experiencing noticeable memory or thinking changes (Subjective Cognitive Decline), or have a clinical diagnosis of Mild Cognitive Impairment (MCI) or dementia.
Have access to a computer, laptop, or tablet with a reliable internet connection.
Are able to provide informed consent, or have a legally authorized Substitute Decision Maker (SDM) who can provide consent on your behalf.
Have adequate vision and motor skills to view a screen and tap or click to respond to prompts (such as a choice reaction time task), using glasses or standard aids if necessary.
Are able to read and communicate in English.
Do not have comorbid psychiatric conditions that interfere with cognitive function Do not have a history of brain injury or neurodevelopmental disorders
Recruitment End Date
- Clinical TrialIn-Person
What is this Study about?
The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 50 months.
Eligibility Criteria
Male or female participants aged 50 years of age
Has a history of previous clinical intracerebral hemorrhage.
Has probable CAA.Recruitment End Date
- Clinical TrialIn-Person
What is this Study about?
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
Eligibility Criteria
Male or female participants aged 50 years of age to 90.
Report of objective or subjective memory concerns (by the participant and/or their informant) within the last year with or without a previous clinical diagnosis of MCI or dementia due to AD.Recruitment End Date
- Clinical TrialIn-Person
What is this Study about?
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment [MCI] to mild dementia due to AD).
Eligibility Criteria
Male or female participants aged 50 years of age to 90.
Must have a study partner
Participant- and/or Informant-reported history of cognitive decline with gradual onset and progression over the last 1 year before screeningRecruitment End Date
- Clinical TrialIn-Person
What is this Study about?
The purpose of this study is to find out whether treatment with VHB937 is safe and beneficial in people with early Alzheimer's disease. The study will evaluate the safety of VHB937, as well as its effects on memory and other thinking abilities, on daily activities, and on changes in the brain. The study will also observe and measure how VHB937 is processed by the body and how the body responds to it.
Official TitleEligibility Criteria
Male or female participants aged 50 years of age to 85.
Must have a study partner
Diagnosis of Mild Cognitive Impairment (MCI) due to AD or mild ADRecruitment End Date
- Observational StudyIn-Person
What is this Study about?
Older adults are at greater risk for experiencing a reduction in cognitive and physical function. It is imperative that we identify health behaviors and non-pharmacological (i.e., non-medication) interventions to mitigate these declines. One promising lifestyle intervention to prevent or delay the onset of such declines is exercise, which has been found to improve cognitive function (mental abilities used to perform simple and complex tasks), physical function (muscle mass, bone density) and brain health (structure and function). There is also research demonstrating that creatine, a naturally occurring compound in the body known to decrease with age, can increase muscle mass and bone density in older adults when supplemented. However, it is unclear what effects creatine may have on cognition and brain health in older adults. Thus, our project will investigate the effects of creatine supplementation on cognition and brain health in older adults when combined with different types of exercise. Given the safety, accessibility and known reduction in creatine levels with age, examining how creatine supplementation may benefit older adults is well worth investigating.
Eligibility Criteria
To be eligible to participate in this study you must:
• be 60 years of age or older
• be living independently in the community
• have normal or corrected-to-normal vision and hearing
• read, write, and speak English fluently
• have feelings of memory decline in the past 5 years
• be able to exercise at a moderate pace for 60 minutes 3x/week receive clearance from a medical doctor (once deemed eligible) to participate in an exercise program
You are ineligible to participate in this study if you:
• cannot partake or commit to exercise training 3x/week for 26 weeks or have regularly engaged in exercise (more than once per week) over the past 3 months
• cannot partake or commit to consuming a daily supplement for 26 weeks or consumed nutritional supplements containing creatine monohydrate over the past 3 months
• have a known allergy to creatine monohydrate or dextrose (glucose, D-glucose)
• have been diagnosed with a neurological disorder (e.g., Alzheimer’s disease, Parkinson’s disease)
• have pre-existing kidney disease, heart disease, or liver abnormalities
• have one or more uncontrolled chronic or psychiatric conditions (e.g., hypertension, diabetes, depression, anxiety)
• are taking medication that may impact kidney function (e.g., non-steroidal anti-inflammatory drugs, such as ibuprofen and naproxen)
• are ineligible or uncomfortable with blood sampling.
Recruitment End Date
- Observational StudyIn-Person
What is this Study about?
McMaster University is conducting a study on the effects of brain stimulation in individuals aged 50 and older with dementia or memory loss. The research focuses on using repetitive transcranial magnetic stimulation (rTMS), a noninvasive technique that delivers magnetic pulses to the brain, to enhance cognitive function and balance. The goal is to extend the positive effects of brain stimulation in improving cognition and balance in individuals with dementia.
Eligibility Criteria
1.) Diagnosed with Dementia and/or memory loss by a clinician
2.) Exhibit adequate oral communication skills and cognitive function
3.) Walk or stand with or without personnel or assistive devices
4.) Individuals must be greater than or equal to 50 years of age
Recruitment End Date
Alzheimer Society of Canada
20 Eglinton Avenue West, 16th Floor
Toronto, Ontario M4R 1K8
Telephone: 1-800-616-8816
Email: [email protected]
Charity registration number: 11878 4925 RR0001
Follow us: